Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Public ClinicalTrials.gov record NCT00818441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.
Study identification
- NCT ID
- NCT00818441
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2009 (Actual)
- Primary completion
- Apr 27, 2012 (Actual)
- Completion
- Apr 30, 2015 (Actual)
- Last update posted
- Jan 8, 2019
2009 – 2015
United States locations
- U.S. sites
- 31
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine | Orange | California | 92868-3298 | — |
| Chao Family Comprehensive Cancer Center UC Irvine Medical Center | Orange | California | 92868 | — |
| Bay Area Cancer Research Group, LLC | Pleasant Hill | California | 94523 | — |
| Pacific Cancer Care | Salinas | California | 93901 | — |
| San Francisco General Hospital | San Francisco | California | 94110 | — |
| University of Colorado Clinical Trials Office (CTO) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33919 | — |
| National Institutes of Health National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02210 | — |
| Dana-Farber Cancer lnstitute | Boston | Massachusetts | 02210 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| St. John's Hospital, | Springfield | Missouri | 65804 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10022 | — |
| Stony Brook University Medical Center - Cancer Center | Stony Brook | New York | 11794-9446 | — |
| Investigational Drug Service, Pharmacy Department, UNC Hospitals | Chapel Hill | North Carolina | 27514 | — |
| Division of Hemotology/Oncology | Chapel Hill | North Carolina | 27599-2008 | — |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599-7600 | — |
| Morris Cancer Center | Durham | North Carolina | 27710 | — |
| Legacy Pharma Research | Bismarck | North Dakota | 58501 | — |
| Mid Dakota Clinic, P.C | Bismarck | North Dakota | 58501 | — |
| Chattanooga Oncology & Hematology Associates, P.C. | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 (Administration) | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203(Pharmacy) | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00818441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00818441 live on ClinicalTrials.gov.